HC Wainwright Has Bearish Forecast for ELTX Q3 Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Elicio Therapeutics to a loss of $0.44 per share from $0.39, while maintaining a “Buy” rating.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $19.75 price target, despite ratings ranging from Buy to Sell.
• Elicio reported a Q2 loss of $0.43 per share, better than the $0.54 consensus estimate. Shares opened at $3.13, near their 52-week low of $2.66, and institutional investors own 35.03% of the stock.

Elicio Therapeutics, Inc. (NASDAQ:ELTX - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2026 earnings estimates for shares of Elicio Therapeutics in a report released on Tuesday, August 18th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.44) per share for the quarter, down from their prior forecast of ($0.39). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Elicio Therapeutics' current full-year earnings is ($2.10) per share. HC Wainwright also issued estimates for Elicio Therapeutics' Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.83) EPS, Q1 2027 earnings at ($0.35) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.38) EPS.

Several other research firms have also issued reports on ELTX. Rodman & Renshaw reaffirmed a "buy" rating on shares of Elicio Therapeutics in a research note on Monday, June 15th. LADENBURG THALM/SH SH began coverage on Elicio Therapeutics in a research report on Thursday, June 18th. They issued a "buy" rating and a $12.00 price objective for the company. JonesTrading downgraded Elicio Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, June 16th. B. Riley Financial began coverage on shares of Elicio Therapeutics in a research note on Wednesday, June 10th. They set a "buy" rating and a $27.00 price target on the stock. Finally, Wall Street Zen raised Elicio Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, August 15th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Elicio Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $19.75.

Elicio Therapeutics Stock Up 0.6%

Shares of Elicio Therapeutics stock opened at $3.13 on Thursday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.77 and a quick ratio of 2.77. The firm has a market cap of $59.75 million, a price-to-earnings ratio of -1.44 and a beta of 1.30. The stock has a 50-day simple moving average of $3.80 and a 200-day simple moving average of $8.32. Elicio Therapeutics has a 52-week low of $2.66 and a 52-week high of $16.00.

Elicio Therapeutics (NASDAQ:ELTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.11.

Institutional Trading of Elicio Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELTX. Royal Bank of Canada acquired a new stake in shares of Elicio Therapeutics during the 1st quarter worth approximately $225,000. Jane Street Group LLC bought a new stake in shares of Elicio Therapeutics in the 1st quarter valued at $92,000. Geode Capital Management LLC increased its holdings in shares of Elicio Therapeutics by 56.0% in the second quarter. Geode Capital Management LLC now owns 120,831 shares of the company's stock worth $933,000 after acquiring an additional 43,364 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Elicio Therapeutics during the 2nd quarter worth approximately $46,000. Finally, Vanguard Group Inc. increased its position in shares of Elicio Therapeutics by 4.2% during the third quarter. Vanguard Group Inc. now owns 473,859 shares of the company's stock worth $5,184,000 after acquiring an additional 19,240 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source